ClinicaliQ Trial Snapshot
- Phase 1 Study of ADX-626 in Healthy Participants — Recruiting • Phase I • NCT07081503.
- Early safety testing of new drug ADX-626 in healthy volunteers to check it's tolerable and how the body processes it.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626). Conditions: Healthy Adult Participants Interventions: ADX-626, Placebo Lead Sponsor: ADARx Pharmaceuticals, Inc. Planned Enrollment: 44 participants